HTB

2024

Lenacapavir submitted to the US FDA with an indication for HIV PrEP

Chiva short films on children and HIV shortlisted for charity award

HIVR4P 2024 conference resources now open access

Tecovirimat fails to show benefit in randomised STOMP study in mpox clade 2

IAS-USA 2024 guidelines for HIV treatment and prevention: some differences to EACS and UK

i-Base guides updated online

Future meetings and webinars 2025

Glasgow HIV Congress 2024: Introduction and links

Once-weekly oral ART with islatravir plus lenacapavir sustains results to week 48

EACS guidelines: New format and contents includes chemsex

Double dose start for oral PrEP in new EACS guidelines – rapid protection in two hours

Future PrEP and new results from PURPOSE 1 and 2 – does HIV exposure explain incident cases?

Liverpool University Drug Interaction website recognised for global impact on research and care

HCV coinfection approaches zero in Spain: but cirrhosis and reinfection among gay men are still significant even with high rates of cure

Dolutegravir/lamivudine vs triple ART have similar efficacy in advanced HIV infection with CD4 <200 and viral load >100,000

Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan

WHO toolkit to strengthen engagement of health workers in emergency responses

HTB news: i-Base changes during 2024

Bipolar disorder in people living with HIV

Mpox breakthrough cases after two doses of the MVA-BN vaccine

Management of drug resistance to integrase inhibitors: results from an international perinatal virtual clinic

Confirmed mpox clade 1b case in Germany: risk remains low for EU/EEA

Helsinki Declaration: 2024 edition upholds ethical access to treatment

Lack of tecovirimat activity against mpox clade 1

Efficacy of MVA-BN vaccine: systematic review

Kidney transplants from HIV positive donors to HIV recipients

US NIAID updates HIV guide to person-centred language

Long COVID essentials: link to online resources

Urgency of planning broad vaccine-like access to lenacapavir PrEP globally

Impact on CD4 counts of once-monthly islatravir in PrEP studies: early macaque results with MK-8527 follow-on compound

Lenacapavir PrEP in cisgender gay men, trans and gender-diverse people: results of the PURPOSE 2 study

HIVR4P 2024: Context of PrEP in Latin America

HIVR4P 2024: Introduction

HIV diagnoses in England jump by 51% in 2023: missing targets and highlighting disparities in access to care

Mpox outbreak in Australia: half of cases had previously received a vaccine

Gilead announces plans to support generic lenacapavir for low-income countries

WHO situation report on mpox

Major update of UK PrEP guidelines online for public consultation

NICE defers decision on CAB-LA as PrEP needing more information

Second lenacapavir PrEP study protected 99.9% of people in the PURPOSE 2 trial: ACT UP London challenge pricing

UNAIDS reports debt crisis obstructs HIV response

i-Base library archived at the Bishopsgate Institute and Wellcome Collection

New HIV drug interactions, statin resource and free hybrid workshop

UK orders 150,000 doses of MVA-BN mpox vaccine

ART, weight changes and obesity: results from CASCADE cohort

Activist pin-up calendar from ACT UP London

AIDS 2024: Including people living with HIV in non-HIV research

New guidelines for HIV-related lymphoma

Responses to mpox clade 1b emergency: webinar details

IAS 2024: Open letter to IAS over online access

WHO declares new mpox emergency (clade 1b): tecovirimat not effective in DRC study

AIDS 2024: Ten early reports

BMS to discontinue atazanavir/cobicistat (Evotaz) in September 2024

Five days on two days off: Biktarvy in pilot FOTO study

Subcutaneous formulation of long-acting CAB/RPV discontinued

First data on third-generation integrase inhibitor from ViiV

Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study

AIDS 2024: Lenacapavir as PrEP is “beyond wonderful” but PURPOSE 1 study tells us so much more 

Low efficacy and high price of dapivirine ring: not included as PrEP in South African guidelines

Semaglutide in people with HIV: reduces both central and peripheral fat worsening lipoatrophy

Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV

Updated WHO guidelines for HIV PEP (July 2024)

AIDS 2024: Introduction to AIDS 2024

UNAIDS report: The urgency of now – AIDS at a crossroads.

New community call to challenge social settings that drive HIV-related stigma

Post navigation